BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dittmar Y, Settmacher U. Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World J Gastrointest Oncol 2015; 7(11): 292-302 [PMID: 26600929 DOI: 10.4251/wjgo.v7.i11.292]
URL: https://www.wjgnet.com/1948-5204/full/v7/i11/292.htm
Number Citing Articles
1
Aftab Amin, Muhammad Jahangir Hossen, Xiu-Qiong Fu, Ji-Yao Chou, Jia-Ying Wu, Xiao-Qi Wang, Ying-Jie Chen, Ying Wu, Cheng-Le Yin, Xiao-Bing Dou, Chun Liang, Gui-Xin Chou, Zhi-Ling Yu. Inhibition of the Akt/NF-κB pathway is involved in the anti-gastritis effects of an ethanolic extract of the rhizome of Atractylodes macrocephalaJournal of Ethnopharmacology 2022; 293: 115251 doi: 10.1016/j.jep.2022.115251
2
Natalia Ortiz, Juan Carlos Delgado-Carazo, Cecilia Díaz. Importance of Mevalonate Pathway Lipids on the Growth and Survival of Primary and Metastatic Gastric Carcinoma CellsClinical and Experimental Gastroenterology 2021; : 217 doi: 10.2147/CEG.S310235
3
Li Yang, Xian-Zhe Dong, Xiao-Xuan Xing, Xiao-Hui Cui, Lin Li, Lan Zhang. Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysisWorld Journal of Gastrointestinal Oncology 2020; 12(11): 1346-1363 doi: 10.4251/wjgo.v12.i11.1346
4
Wei Zhu, Liang Ye, Jianzhao Zhang, Pengfei Yu, Hongbo Wang, Zuguang Ye, Jingwei Tian, Irina V Lebedeva. PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric CancerPLOS ONE 2016; 11(9): e0163768 doi: 10.1371/journal.pone.0163768
5
Ling Qiu, Hui Yang, Gaochao Lv, Ke Li, Guiqing Liu, Wei Wang, Shanshan Wang, Xueyu Zhao, Minhao Xie, Jianguo Lin. Insights into the mevalonate pathway in the anticancer effect of a platinum complex on human gastric cancer cellsEuropean Journal of Pharmacology 2017; 810: 120 doi: 10.1016/j.ejphar.2017.06.035
6
Hong Meng, Jing Li, Huapeng Sun, Yanxin Lin, Haisheng Xu, Na Zhang. The transcription factor ATF2 promotes gastric cancer progression by activating the METTL3/cyclin D1 pathwayDrug Development Research 2023; 84(6): 1325 doi: 10.1002/ddr.22092
7
Beverly A. Teicher. Immunotherapy for Gastrointestinal Cancer2017; : 79 doi: 10.1007/978-3-319-43063-8_4
8
Shigenobu Motoshima, Koji Yonemoto, Hideki Kamei, Michi Morita, Rin Yamaguchi. Prognostic implications of HER2 heterogeneity in gastric cancerOncotarget 2018; 9(10): 9262 doi: 10.18632/oncotarget.24265
9
Wenjie Liu, Gengwei Huo, Peng Chen. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysisImmunotherapy 2023; 15(10): 751 doi: 10.2217/imt-2022-0305
10
Ying Fu, Hui Li, Xishan Hao. The self-renewal signaling pathways utilized by gastric cancer stem cellsTumor Biology 2017; 39(4): 101042831769757 doi: 10.1177/1010428317697577
11
Xiaofei Ni, Yanpeng Xing, Xuan Sun, Jian Suo. The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trialsClinics and Research in Hepatology and Gastroenterology 2020; 44(2): 211 doi: 10.1016/j.clinre.2019.05.007
12
Minghui Zhang, Yuandi Dong, Haitao Liu, Yan Wang, Shu Zhao, Qijia Xuan, Yan Wang, Qingyuan Zhang. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patientsScientific Reports 2016; 6(1) doi: 10.1038/srep37933
13
Gengwei Huo, Wenjie Liu, Peng Chen. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysisBMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-10605-y